Down-regulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors

International Journal of Oncology

Volumn 38, Issue 2, 2011, Pages 503-511

  Koelz, Marita ^a   Lense, Josefine ^b   Wrba, Fritz ^a   Scheffler, Melanie ^b   Dienes, Hans Peter ^b   Odenthal, Margarete ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Gastrointestinal stromal tumors; Kit expression; MicroRNA 221; MicroRNA 222; New therapeutic tool

Indexed keywords

MICRORNA; MICRORNA 221; MICRORNA 222; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; DOWN REGULATION; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C KIT; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH;

DOWN-REGULATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOENZYME TECHNIQUES; MICRORNAS; MUTATION; NEVUS, SPINDLE CELL; PARAFFIN EMBEDDING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 78651243203     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2010.857     Document Type: Article

References (50)

1. Miettinen M and Lasota J: Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466-1478, 2006.
2. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465, 2002. (Pubitemid 34747864)
3. Badalamenti G, Rodolico V, Fulfaro F, et al: Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Ann Oncol 18 (Suppl 6): 136-140, 2007.
4. Rubin BP: Gastrointestinal stromal tumours: an update. Histopathology 48: 83-96, 2006.
5. Fletcher JA and Rubin BP: KIT mutations in GIST. Curr Opin Genet Dev 17: 3-7, 2007.
6. Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154: 53-60, 1999.
7. Lasota J, Wozniak A, Sarlomo-Rikala M, et al: Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 157: 1091-1095, 2000.
8. Corless CL, McGreevey L, Haley A, Town A and Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160: 1567-1572, 2002.
9. Gold JS and Dematteo RP: Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 244: 176-184, 2006.
10. Sleijfer S, Wiemer E and Verweij J: Drug Insight: gastrointestinal stromal tumors (GIST) - the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 5: 102-111, 2008.
11. Debiec-Rychter M, Dumez H, Judson I, et al: Use of c-KIT/ PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689-695, 2004.
12. Hornick JL and Fletcher CD: The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol 38: 679-687, 2007.
13. Nishida T, Kanda T, Nishitani A, et al: Secondary mutations in the kinase domain of the KIT gene are predominant in imatinibresistant gastrointestinal stromal tumor. Cancer Sci 99: 799-804, 2008.
14. Antonescu CR, Besmer P, Guo T, et al: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190, 2005.
15. Tabone S, Theou N, Wozniak A, et al: KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim Biophys Acta 1741: 165-172, 2005.
16. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.
17. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
18. Kumar MS, Lu J, Mercer KL, Golub TR and Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677, 2007.
19. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
20. Filipowicz W, Jaskiewicz L, Kolb FA and Pillai RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr Opin Struct Biol 15: 331-341, 2005.
21. Carleton M, Cleary MA and Linsley PS: MicroRNAs and cell cycle regulation. Cell Cycle 6: 2127-2132, 2007.
22. Schickel R, Boyerinas B, Park SM and Peter ME: MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27: 5959-5974, 2008.
23. Ma L and Weinberg RA: MicroRNAs in malignant progression. Cell Cycle 7: 570-572, 2008.
24. Kent OA and Mendell JT: A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196, 2006.
25. Cowland JB, Hother C and Gronbaek K: MicroRNAs and cancer. APMIS 115: 1090-1106, 2007.
26. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
27. Wijnhoven BP, Michael MZ and Watson DI: MicroRNAs and cancer. Br J Surg 94: 23-30, 2007.
28. Cimmino A, Calin GA, Fabbri M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005.
29. Johnson CD, Esquela-Kerscher A, Stefani G, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7713-7722, 2007.
30. Akao Y, Nakagawa Y and Naoe T: MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 26: 311-320, 2007.
31. Akao Y, Nakagawa Y and Naoe T: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 16: 845-850, 2006.
32. He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature 435: 828-833, 2005.
33. Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 102: 3627-3632, 2005.
34. Tam W and Dahlberg JE: miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer 45: 211-212, 2006.
35. Felli N, Fontana L, Pelosi E, et al: MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 102: 18081-18086, 2005.
36. Felicetti F, Errico MC, Bottero L, et al: The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68: 2745-2754, 2008.
37. Galardi S, Mercatelli N, Giorda E, et al: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716-23724, 2007.
38. Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 14: 791-798, 2007.
39. He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005.
40. Fornari F, Gramantieri L, Ferracin M, et al: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 27: 5651-5661, 2008.
41. Gillies JK and Lorimer IA: Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 6: 2005-2009, 2007.
42. Pallante P, Visone R, Ferracin M, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13: 497-508, 2006.
43. Lee EJ, Gusev Y, Jiang J, et al: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 120: 1046-1054, 2007. (Pubitemid 46214304)
44. Schulte S, Oidtmann A, Kociok N, et al: Hepatocyte expression of angiotensin II type 1 receptor is downregulated in advanced human liver fibrosis. Liver Int 29: 384-391, 2008.
45. Wedemeyer I, Bechmann LP, Odenthal M, et al: Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: Therapeutic implications for hepatitis C. J Hepatol 50: 140-149, 2009.
46. Varnholt H, Drebber U, Schulze F, et al: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232, 2008.
47. Ciafre SA, Galardi S, Mangiola A, et al: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334: 1351-1358, 2005.
48. Le Sage C, Nagel R, Egan DA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26: 3699-3708, 2007.
49. Tsuda N, Ishiyama S, Li Y, Ioannides CG, Abbruzzese JL and Chang DZ: Synthetic microRNA designed to target gliomaassociated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin Cancer Res 12: 6557-6564, 2006.
50. Krutzfeldt J, Rajewsky N, Braich R, et al: Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689, 2005.